ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Search Videos by Topic or Participant
Browse by Series:

Introduction and Exploration of Fulvestrant in Breast Cancer

Panelists: Adam M. Brufsky, MD, PhD, University of Pittsburgh; Sara Hurvitz, MD, UCLA;Joyce A. O'Shaughnessy, MD, US Oncology; Edith A. Perez, MD,
Published: Sunday, Jun 09, 2013
For High-Definition, Click
Moderator, Adam M. Brufsky, MD, PhD, introduces the panel for an in-depth discussion analyzing recent trials that explored the detection, management, and treatment of metastatic breast cancer. The expert panel includes: Sara Hurvitz, MD, Joyce O’Shaughnessy, MD, Edith A. Perez, MD, Hope S. Rugo, MD, and Andrew D. Seidman, MD.

To begin the conversation, O'Shaughnessy describes the CONFIRM trial, which compared a 250 mg dose of fulvestrant to the now approved 500 mg dose. In this trial, the larger dose of fulvestrant was shown to be superior and is now the standard of care. Additionally, the FALCON trial is comparing the now approved 500 mg dose of fulvestrant to anastrozole in the first-line for patients with advanced breast cancer.

The equivocal findings from a comparison of the 250mg dose of fulvestrant to exemestane and an evaluation of pharmacokinetics raised interests in a higher dose, Perez notes. Initially, Rugo notes, researchers had doubts about whether 250 mg was actually the maximum tolerated dose, which also led to further research and the approval of the 500 mg dose. This stresses the importance of discovering the maximum tolerated dose in clinical trials, Rugo believes.

Seidman believes the 500 mg dose is correct, especially leading into trials exploring combinations.
Slider Left
Slider Right
For High-Definition, Click
Moderator, Adam M. Brufsky, MD, PhD, introduces the panel for an in-depth discussion analyzing recent trials that explored the detection, management, and treatment of metastatic breast cancer. The expert panel includes: Sara Hurvitz, MD, Joyce O’Shaughnessy, MD, Edith A. Perez, MD, Hope S. Rugo, MD, and Andrew D. Seidman, MD.

To begin the conversation, O'Shaughnessy describes the CONFIRM trial, which compared a 250 mg dose of fulvestrant to the now approved 500 mg dose. In this trial, the larger dose of fulvestrant was shown to be superior and is now the standard of care. Additionally, the FALCON trial is comparing the now approved 500 mg dose of fulvestrant to anastrozole in the first-line for patients with advanced breast cancer.

The equivocal findings from a comparison of the 250mg dose of fulvestrant to exemestane and an evaluation of pharmacokinetics raised interests in a higher dose, Perez notes. Initially, Rugo notes, researchers had doubts about whether 250 mg was actually the maximum tolerated dose, which also led to further research and the approval of the 500 mg dose. This stresses the importance of discovering the maximum tolerated dose in clinical trials, Rugo believes.

Seidman believes the 500 mg dose is correct, especially leading into trials exploring combinations.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Community Practice Connections: Oncology Best Practice™ Targeting Cell Cycle Progression: The Latest Advances on CDK4/6 Inhibition in Metastatic Breast CancerOct 31, 20181.0
Publication Bottom Border
Border Publication
x